CN105647946B - 一种基于FcγRⅢa的嵌合基因及其用途 - Google Patents
一种基于FcγRⅢa的嵌合基因及其用途 Download PDFInfo
- Publication number
- CN105647946B CN105647946B CN201610156775.7A CN201610156775A CN105647946B CN 105647946 B CN105647946 B CN 105647946B CN 201610156775 A CN201610156775 A CN 201610156775A CN 105647946 B CN105647946 B CN 105647946B
- Authority
- CN
- China
- Prior art keywords
- iii
- cell
- mosaic gene
- seq
- mosaic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (19)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610156775.7A CN105647946B (zh) | 2016-03-18 | 2016-03-18 | 一种基于FcγRⅢa的嵌合基因及其用途 |
CN201910990200.9A CN110699371A (zh) | 2016-03-18 | 2016-03-18 | 一种基于FcγRⅢa的嵌合基因及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610156775.7A CN105647946B (zh) | 2016-03-18 | 2016-03-18 | 一种基于FcγRⅢa的嵌合基因及其用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910990200.9A Division CN110699371A (zh) | 2016-03-18 | 2016-03-18 | 一种基于FcγRⅢa的嵌合基因及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105647946A CN105647946A (zh) | 2016-06-08 |
CN105647946B true CN105647946B (zh) | 2019-09-20 |
Family
ID=56495068
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610156775.7A Active CN105647946B (zh) | 2016-03-18 | 2016-03-18 | 一种基于FcγRⅢa的嵌合基因及其用途 |
CN201910990200.9A Pending CN110699371A (zh) | 2016-03-18 | 2016-03-18 | 一种基于FcγRⅢa的嵌合基因及其用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910990200.9A Pending CN110699371A (zh) | 2016-03-18 | 2016-03-18 | 一种基于FcγRⅢa的嵌合基因及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN105647946B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018013962A1 (en) * | 2016-07-15 | 2018-01-18 | Viracta Therapeutics, Inc. | Histone deacetylase inhibitors for use in immunotherapy |
WO2018069927A1 (en) * | 2016-10-10 | 2018-04-19 | The National Institute for Biotechnology in the Negev Ltd. | Non-cytotoxic modified cells and use thereof |
CN110204619B (zh) * | 2019-06-11 | 2020-06-05 | 南京融捷康生物科技有限公司 | 包含FcγRⅠ的嵌合抗原受体及其应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103145849A (zh) * | 2013-02-18 | 2013-06-12 | 冯振卿 | 嵌合抗原受体及其用途 |
CN104136458A (zh) * | 2012-02-22 | 2014-11-05 | 宾夕法尼亚大学董事会 | 在第二代嵌合抗原受体中cd2信号传导结构域的使用 |
CN104718223A (zh) * | 2012-08-20 | 2015-06-17 | 格利克尼克股份有限公司 | 具有抗原结合和多价FCγ受体结合活性的分子 |
CN104829733A (zh) * | 2015-05-25 | 2015-08-12 | 广州科锐特生物科技有限公司 | 抗原结合单元稳定的嵌合抗原受体及制备方法与应用 |
CN104961833A (zh) * | 2015-07-21 | 2015-10-07 | 中国科学技术大学 | 一种人源NKp80-Fc融合蛋白及其制备方法和在肿瘤治疗中的应用 |
CN105177031A (zh) * | 2015-06-12 | 2015-12-23 | 北京艺妙神州医疗科技有限公司 | 嵌合抗原受体修饰的t细胞及其用途 |
CN105296431A (zh) * | 2015-11-26 | 2016-02-03 | 中国医学科学院基础医学研究所 | 肿瘤结合特异性γδTCR基因修饰的αβT细胞及其抑癌用途 |
CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药(上海)有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
CN105384825A (zh) * | 2015-08-11 | 2016-03-09 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
US10144770B2 (en) * | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
-
2016
- 2016-03-18 CN CN201610156775.7A patent/CN105647946B/zh active Active
- 2016-03-18 CN CN201910990200.9A patent/CN110699371A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104136458A (zh) * | 2012-02-22 | 2014-11-05 | 宾夕法尼亚大学董事会 | 在第二代嵌合抗原受体中cd2信号传导结构域的使用 |
CN104718223A (zh) * | 2012-08-20 | 2015-06-17 | 格利克尼克股份有限公司 | 具有抗原结合和多价FCγ受体结合活性的分子 |
CN103145849A (zh) * | 2013-02-18 | 2013-06-12 | 冯振卿 | 嵌合抗原受体及其用途 |
CN104829733A (zh) * | 2015-05-25 | 2015-08-12 | 广州科锐特生物科技有限公司 | 抗原结合单元稳定的嵌合抗原受体及制备方法与应用 |
CN105177031A (zh) * | 2015-06-12 | 2015-12-23 | 北京艺妙神州医疗科技有限公司 | 嵌合抗原受体修饰的t细胞及其用途 |
CN104961833A (zh) * | 2015-07-21 | 2015-10-07 | 中国科学技术大学 | 一种人源NKp80-Fc融合蛋白及其制备方法和在肿瘤治疗中的应用 |
CN105384825A (zh) * | 2015-08-11 | 2016-03-09 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药(上海)有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
CN105296431A (zh) * | 2015-11-26 | 2016-02-03 | 中国医学科学院基础医学研究所 | 肿瘤结合特异性γδTCR基因修饰的αβT细胞及其抑癌用途 |
Non-Patent Citations (3)
Title |
---|
CAR T-cell therapy:toxicity and the relevance of preclinical models.;Kalaitsidou M 等;《Immunotherapy》;20150612;第7卷(第5期);第487-497页 * |
嵌合抗原受体基因修饰T淋巴细胞在肿瘤免疫治疗中的研究;蔡慧 等;《现代肿瘤医学》;20141008;第22卷(第11期);第2730-2734页 * |
治疗性单克隆抗体的作用靶点及临床应用概述;陈炅 等;《中国药师》;20131205;第16卷(第12期);第1930-1933页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110699371A (zh) | 2020-01-17 |
CN105647946A (zh) | 2016-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7012056B2 (ja) | 養子細胞療法薬を製造するための改善された方法 | |
CN107249602B (zh) | 靶向血液恶性肿瘤之嵌合抗原受体(car)、其组合物及使用方法 | |
US10647778B2 (en) | Bi-specific chimeric antigen receptor and uses thereof | |
JP2024056890A (ja) | 前立腺特異的膜抗原carおよびその使用方法 | |
EP2771355B1 (en) | A MODIFIED EFFECTOR CELL (OR CHIMERIC RECEPTOR) FOR TREATING DISIALOGANGLIOSIDE Gp2-EXPRESSING NEOPLASIA | |
KR20200023165A (ko) | 단일 도메인 항체에 기반한 bcma 키메라 항원 수용체 및 응용 | |
MX2014003176A (es) | Celulas t diseñadas mediante arn para el tratamiento de cancer. | |
WO2021057823A1 (en) | Ror1 specific chimeric antigen receptors and their therapeutic applications | |
CN107058354A (zh) | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 | |
KR20200000495A (ko) | 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구 | |
CN103502438A (zh) | 用于细胞免疫治疗的方法和组合物 | |
JP2021531008A (ja) | Gd2に基づくキメラ抗原受容体及びその利用 | |
CN105296431A (zh) | 肿瘤结合特异性γδTCR基因修饰的αβT细胞及其抑癌用途 | |
CN109776671A (zh) | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 | |
CN113416260B (zh) | 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用 | |
CN113896801B (zh) | 靶向人Claudin18.2和NKG2DL的嵌合抗原受体细胞及其制备方法和应用 | |
AU2018349093A1 (en) | T cell-antigen coupler with Y182T mutation and methods and uses thereof | |
CN113788894A (zh) | 靶向人Claudin18.2蛋白的单克隆抗体及其应用 | |
CN105647946B (zh) | 一种基于FcγRⅢa的嵌合基因及其用途 | |
CN110204619B (zh) | 包含FcγRⅠ的嵌合抗原受体及其应用 | |
WO2023102504A1 (en) | Chimeric antigen receptor therapies and vasoactive intestinal peptide receptor antagonists | |
CN110577932A (zh) | 一种脐带血来源的嵌合抗原受体t细胞 | |
CN116396389B (zh) | 一种靶向bcma的单域抗体、嵌合抗原受体及其应用 | |
CN117164712B (zh) | 一种靶向cd22的单域抗体、嵌合抗原受体及其应用 | |
CN117402247B (zh) | 一种靶向cd5的单域抗体、嵌合抗原受体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20161012 Address after: 26, 58, No. 215000, Xin Lu, Suzhou Industrial Park, Suzhou, Jiangsu, A002 Applicant after: Puri Ji Xuan biomedical science and Technology (Suzhou) Co., Ltd. Address before: 215000, room 25, building 78, 802 Xin Xin Dong Road, Suzhou, Jiangsu, Wuzhong District Applicant before: SUZHOU KANGYUAN BIOLOGICAL TECHNOLOGY CO., LTD. |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20170718 Address after: 642, room 1, Shunda Commercial Plaza, Suzhou Industrial Park, Suzhou, Jiangsu, 215000 Applicant after: SUZHOU KANGYUAN BIOLOGICAL TECHNOLOGY CO., LTD. Address before: 26, 58, No. 215000, Xin Lu, Suzhou Industrial Park, Suzhou, Jiangsu, A002 Applicant before: Puri Ji Xuan biomedical science and Technology (Suzhou) Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20181024 Address after: 215000 201 units of Tengfei science and Technology Park, 388 Xinping street, Suzhou Industrial Park, Jiangsu, China, 23 Applicant after: Jiangsu Pro Health biotech Co., Ltd. Address before: 215000 room 642, Shunda Commercial Plaza, Suzhou Industrial Park, Suzhou, Jiangsu, 642 Applicant before: SUZHOU KANGYUAN BIOLOGICAL TECHNOLOGY CO., LTD. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |